Expertise in
26
conditions

Dr. Uchenna O. Njiaju

Oncology
Memorial Health System
1400 E Boulder St, 
Colorado Springs, CO 
Accepting New Patients
Offers Telehealth
Expertise in
26
conditions
Memorial Health System
1400 E Boulder St, 
Colorado Springs, CO 

Overview

Uchenna Njiaju is an Oncologist practicing medicine in Colorado Springs, Colorado.

Dr. Njiaju is highly rated in 26 conditions, according to our data. Her clinical expertise encompasses Paget Disease of the Breast, Breast Cancer, Inflammatory Breast Cancer, and Angiosarcoma.

She is actively involved in clinical research, co-authoring 8 peer reviewed articles and participating in 6 clinical trials. Dr. Njiaju is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in WI

Hospital Affiliations

Uch-Memorial Health System
University Of Colorado Hospital Authority
Uchealth Grandview Hospital
Uchealth Pikes Peak Regional Hospital
Parkview Medical Center, Inc

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

Memorial Health System
1400 E Boulder St, Colorado Springs, CO 80909
Other Locations
Uch-MHS Memorial Hospital North Poc
4050 Briargate Pkwy, Colorado Springs, CO 80920

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Enrollment Status: Active_not_recruiting
Publish Date: July 23, 2026
Intervention Type: Drug
Study Drugs: tucatinib, T-DM1
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
Phase I/II Trial of Radiotherapy in Combination With Atezolizumab Prior to Surgical Resection for HPV-unrelated Squamous Cell Carcinoma of the Head and Neck (HNSCC)
Phase I/II Trial of Radiotherapy in Combination With Atezolizumab Prior to Surgical Resection for HPV-unrelated Squamous Cell Carcinoma of the Head and Neck (HNSCC)
Enrollment Status: Completed
Publish Date: February 03, 2025
Intervention Type: Drug, Radiation
Study Drug: Atezolizumab
Study Phase: Phase 1
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Enrollment Status: Terminated
Publish Date: March 23, 2022
Intervention Type: Drug
Study Drugs: Trilaciclib, Gemcitabine, Carboplatin
Study Phase: Phase 2
A Single-Arm, Global, Phase 4 Study of Abemaciclib, a CDK 4 & 6 Inhibitor, in Combination With Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) in Participants With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer With Poor Prognostic Factors
A Single-Arm, Global, Phase 4 Study of Abemaciclib, a CDK 4 & 6 Inhibitor, in Combination With Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) in Participants With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer With Poor Prognostic Factors
Enrollment Status: Withdrawn
Publish Date: September 06, 2019
Intervention Type: Drug
Study Phase: Phase 4
View 5 Less Clinical Trials

8 Total Publications

A 40-Year-Old Woman With a New Triple-Negative Breast Mass, Shown on Biopsy to Be Metaplastic Carcinoma.
A 40-Year-Old Woman With a New Triple-Negative Breast Mass, Shown on Biopsy to Be Metaplastic Carcinoma.
Journal: Oncology (Williston Park, N.Y.)
Published: July 20, 2016
Similar Doctors
Expertise in
66
conditions
Expertise in
66
conditions
Referral may be required

Rocky Mountain Cancer Centers

1700 S Potomac St, 
Aurora, CO 
 (58.4 miles away)
303-418-7600
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

John Burke is an Oncologist practicing medicine in Aurora, Colorado. Dr. Burke is highly rated in 66 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Classical Hodgkin Lymphoma, Chronic Lymphocytic Leukemia (CLL), and Nephrectomy. Dr. Burke is board certified in American Board Of Internal Medicine. Dr. Burke is currently accepting new patients.

Expertise in
15
conditions
Dr. Nicholas K. Foreman
Hematology | Oncology
Expertise in
15
conditions
Dr. Nicholas K. Foreman
Hematology | Oncology
Referral may be required

Children's Hospital Colorado

1811 Plaza Dr, 
Highlands Ranch, CO 
 (50.8 miles away)
720-478-9840
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Nicholas Foreman is a Hematologist and an Oncologist practicing medicine in Highlands Ranch, Colorado. Dr. Foreman is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Ependymoma, Brain Tumor, Medulloblastoma, and Ganglioglioma. Dr. Foreman is currently accepting new patients.

Expertise in
13
conditions
Expertise in
13
conditions
Referral may be required

UCHealth Southern Colorado Gynecologic Oncology Clinic

525 Bob Peters Grv Ste 309, 
Colorado Springs, CO 
 (1.6 miles away)
719-365-6464
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Dirk Pikaart is an Oncologist practicing medicine in Colorado Springs, Colorado. Dr. Pikaart is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Endometrial Cancer, Vulvar Cancer, Malignant Mixed Mullerian Tumor, Splenectomy, and Hernia Surgery. Dr. Pikaart is currently accepting new patients.

Frequently Asked Questions about Dr. Uchenna O. Njiaju

How do I make an appointment with Dr. Uchenna O. Njiaju?

You can book an appointment with Dr. Uchenna O. Njiaju by calling their office at 719-365-5000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Uchenna O. Njiaju a top-rated expert for Paget Disease of the Breast?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Uchenna O. Njiaju is classified as an Distinguished expert for Paget Disease of the Breast, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Uchenna O. Njiaju specialize in?

While Dr. Uchenna O. Njiaju is a Oncology, they have specific expertise in Paget Disease of the Breast, Breast Cancer, and Inflammatory Breast Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Uchenna O. Njiaju participate in research or clinical trials?

Yes. Dr. Uchenna O. Njiaju has published 8 articles and abstracts on conditions like Paget Disease of the Breast. You can view a list of Dr. Uchenna O. Njiaju's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Uchenna O. Njiaju accept my insurance?

Dr. Uchenna O. Njiaju accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 719-365-5000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Njiaju's expertise for a condition
ConditionClose
    View All 8 Distinguished Conditions
    View All 18 Advanced Conditions
    View All 68 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile